IMDX Insight Molecular Diagnostics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMDX

Price (delayed)

$3.91

Market cap

$127.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.51

Enterprise value

$112.09M

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 30
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 17

Oncocyte Corporation is a molecular diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid ...

Highlights
The company's EPS has surged by 61% YoY
IMDX's debt is down by 22% year-on-year and by 14% since the previous quarter
Insight Molecular Diagnostics's net income has increased by 22% YoY but it has decreased by 3.2% QoQ
Insight Molecular Diagnostics's equity has shrunk by 99% QoQ
Insight Molecular Diagnostics's gross profit has shrunk by 65% YoY and by 18% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.oncocyte.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of IMDX

IMDX stock price

How has the Insight Molecular Diagnostics stock price performed over time
Intraday
-5.56%
1 week
9.22%
1 month
-9.91%
1 year
29.9%
YTD
-47.87%
QTD
-33.73%

Financial performance

How have Insight Molecular Diagnostics's revenue and profit performed over time
Revenue
$1.67M
Gross profit
$807,000
Operating income
-$50.3M
Net income
-$49.36M
Gross margin
48.3%
Net margin
-2,955.6%
The operating margin has shrunk by 101% YoY and by 20% QoQ
IMDX's net margin has dropped by 98% year-on-year and by 20% since the previous quarter
Insight Molecular Diagnostics's gross profit has shrunk by 65% YoY and by 18% QoQ
The revenue has shrunk by 61% YoY and by 14% QoQ

Price vs fundamentals

How does IMDX's price correlate with its fundamentals

Growth

What is Insight Molecular Diagnostics's growth rate over time

Valuation

What is Insight Molecular Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
86.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
67.12
The company's EPS has surged by 61% YoY
Insight Molecular Diagnostics's equity has shrunk by 99% QoQ
The price to sales (P/S) is 95% more than the 5-year quarterly average of 46.7 and 36% more than the last 4 quarters average of 67.1
The revenue has shrunk by 61% YoY and by 14% QoQ

Efficiency

How efficient is Insight Molecular Diagnostics business performance
The company's return on sales has shrunk by 98% YoY and by 20% QoQ
IMDX's ROIC is down by 25% since the previous quarter and by 22% year-on-year
IMDX's return on assets is down by 21% year-on-year and by 19% since the previous quarter

Dividends

What is IMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMDX.

Financial health

How did Insight Molecular Diagnostics financials performed over time
IMDX's total assets is 42% smaller than its total liabilities
IMDX's quick ratio has dropped by 54% year-on-year and by 25% since the previous quarter
The current ratio has plunged by 50% YoY and by 21% from the previous quarter
IMDX's debt is 112% greater than its equity
The debt to equity has dropped by 104% year-on-year but it has surged by 59% since the previous quarter
Insight Molecular Diagnostics's equity has shrunk by 99% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.